ACTRN12619001308189招募中2 期
BCT 1902 (Neo-N): A phase II trial evaluating the efficacy of nivolumab or nivolumab plus relatlimab with paclitaxel and carboplatin as neoadjuvant therapy in early stage triple negative breast cancers
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 162
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1) Female or male, age >= 18 years.
- •2) Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- •3) Previously untreated non-metastatic (M0) TNBC meeting Stage I or II criteria according to AJCC Cancer Staging Manual, 8th Edition, 2017 as assessed by the local investigator on the basis of mammogram (MMG) and/or ultrasound (US) of the breasts, and US or clinical examination of the axilla.
- •a) Stage I cT1c cN0;
- •Stage IIA cT1 cN1; cT2 cN0;
- •Stage IIB cT2 cN1; cT3 cN0.
- •b) Contralateral in situ only disease is permitted;
- •c) In the event of abnormal imaging of the axilla, nodal status should be confirmed by cytology.
- •4) Clinically node positive participants should undergo computed tomography (CT) scan or PET CT of chest/abdomen (and bone scan if clinically indicated) to exclude metastases. Those participants with equivocal finding on staging should have biopsies performed to confirm or exclude metastatic disease if possible.
- •5) Non-metastatic, potentially operably, unilateral triple negative breast cancer, histologically defined as:
- •a) ER negative: with < 1% of tumour cells positive for ER by IHC irrespective of staining intensity; AND
- •b) PR negative: with < 10% tumour cells positive for PR by IHC irrespective of staining intensity; AND
- •c) HER2 negative:
- •i) IHC 0, as defined by no staining observed or membrane staining that is incomplete and is faint/barely perceptible and within <= 10% of the invasive tumour cells; OR
- •ii) IHC 1+, as defined by incomplete membrane staining that is faint/barely perceptible and within > 10% of invasive tumour cells; OR
- •iii) ISH (FISH or SISH) negative based on:
- •* Single-probe average HER2 copy number < 4.0 signals/cell; OR
- •* Dual-probe HER2/CEP17 ratio < 2.0 with an average HER2 copy number < 4.0 signals/cell; OR
- •* As per ASCO-CAP 2018 Guidelines.
- •6) Able to commence study treatment within 14 days of randomisation/registration.
- •7) Surgery is able to be undertaken within 4 weeks of final dose of neoadjuvant IV therapy. Pre-operative radiation is not permitted for any participant with operable cancer after final paclitaxel.
- •8) Adequate organ function. All screening laboratory tests should be performed within 14 days of randomisation/registration.
- •9) Screening laboratory values must meet the following criteria (using NCI-CTCAE V5.0):
- •a) WBC >= 2 x 10^9/L;
- •b) Neutrophils >= 1.5 x 10^9/L;
- •c) Platelets >= 100 x 10^3/µL;
- •d) Haemoglobin >= 9.0 g/dL;
- •e) Serum creatinine <= 1.5 x ULN or calculated creatinine clearance >= 50 mL/min (using the Cockcroft Gault formula);
- •f) AST/ALT <= 3.0 x ULN;
- •g) Total bilirubin <= 1.5 x ULN except participants with Gilbert Syndrome who must have a total bilirubin level <= 3.0 x ULN.
- •10) Left ventricular ejection fraction (LVEF) of >= 50% assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan performed at screening (no more than 4 weeks before study entry).
- •11) Negative pregnancy test or confirmation of post-menopausal status for female participants. Women who have undergone surgical sterilisation (bilateral oophorectomy, bilateral salpingectomy/tubal ligation, or hysterectomy) do not require pregnancy testing.
- •a) Negative urine or serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG within 14 days of randomisation/registration and within 7 days before the first dose of study treatment. The pregnancy test will be repeated within 24 hours before the first dose if outside this window.
- •b) Women will be con
排除标准
- •1) Confirmed presence of AJCC 8th edition anatomic Stage 3 or 4 disease.
- •2) Tumour of any size considered inoperable at presentation.
- •3) Multifocal* or bilateral invasive breast cancer. * Refer to AJCC 8th Edition: use clinical judgement if satellite nodes are close as to whether this represents truly multifocal disease.
- •4) Has received prior chemotherapy, targeted therapy, radiation therapy, immunotherapy that target immune checkpoints, co-stimulatory or co-inhibitory pathways for T-cell receptors within the past 12 months.
- •5) Will be offered neoadjuvant breast radiation therapy.
- •6) Undergone or planned for sentinel lymph node biopsy before study therapy.
- •7) Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks before randomisation/registration.
- •Note: participant will be excluded if he/she received an investigational agent with anticancer or anti-proliferative intent within the last 12 months.
- •8) Any concurrent anti-neoplastic therapy (i.e. chemotherapy, hormonal therapy, immunotherapy, extensive, non-palliative radiation therapy, or standard or investigational agents for treatment of breast cancer) not already specified in the protocol.
- •9) Prior malignancy active within the previous 3 years before randomisation/registration, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
- •10) Other active non-breast malignancy requiring concurrent intervention.
- •11) Has significant cardiovascular disease such as myocardial infarction, acute coronary syndrome or coronary angioplasty/stenting/bypass grafting within the last 6 months, congestive cardiac failure (CHF) New York Heart Association (NYHA) classification IV or history of CHF NYHA III or IV.
- •12) Participants with an active, known or suspected autoimmune disease are not eligible. Participants with the following are eligible to participate:
- •a) Type I diabetes mellitus;
- •b) Hypothyroidism only requiring hormone replacement;
- •c) Skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment; or
- •d) Conditions not expected to recur in the absence of an external trigger.
- •13) Participants with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomisation/registration are not eligible. Inhaled or topical steroids, and adrenal replacement steroid > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is permitted. Patients requiring steroids as a once-off, short term anti-emetics (such as that prescribed with chemotherapy) are eligible.
- •14) Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity.
- •15) Has a history of non-infectious pneumonitis requiring treatment with steroids.
- •16) Known medical condition that, in the investigator’s opinion, would increase the risk associated with study participation or study drug administration or interfere with the interpretation of safety results.
- •17) Treatment with bot
研究者
相似试验
进行中（未招募）
不适用
A pilot phase II study to assess the efficacy of Brentuximab Vedotin administered sequentally with ABVD chemotherapy in patients with untreated Hodgkin LymphomaEUCTR2012-002012-46-ITAZIENDA OSPEDALIERA POLICLINICO DI MODENA
招募中
2 期
BCT 1901 (CAPTURE): Women or men with oestrogen receptor positive, HER2 negative advanced breast cancer and PIK3CA mutant circulating DNA will be randomised to evaluate treatment with alpelisib plus fulvestrant compared with capecitabine on progression free survival.Advanced Breast CancerACTRN12619001117101Breast Cancer Trials66
进行中（未招募）
2 期
BCT 1702 (CHARIOT): Patients with high-risk primary triple negative breast cancer who have had anthracycline-based chemotherapy will receive Ipilimumab and Nivolumab with weekly paclitaxel, followed by definitive surgery and further treatment with Nivolumab to evaluate the safety, feasibility and efficacy of this treatment.Primary triple negative breast cancerCancer - BreastACTRN12617000651381Breast Cancer Trials34
招募中
不适用
A Phase II trial to evaluate the efficacy of Bortezomib, Cytarabine, and Dexamethasone in patients with relapsed or refractory mantle cell lymphomaKCT0004010Seoul National University Hospital32
已完成
2 期
B2P2M2: Phase II trial of BNC105P as 2nd line chemotherapy for advanced malignant pleural mesotheliomaACTRN12610000093088niversity of Sydney60